Second Affiliated Hospital of Nanchang University

Running trials

• Not yet recruiting

  Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity

  NCT07898267· Second Affiliated Hospital of Nanchang University· Source

• Recruiting

  Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

  NCT07789184· Phase 3· Hua Huang, MD, PhD· Source

• Not yet recruiting

  A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

  NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source

• Not yet recruiting

  A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo

  NCT07865312· Phase 3· Dermavon Holdings Limited· Source

• Not yet recruiting

  Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

  NCT07926607· Phase 1/2· Second Affiliated Hospital of Nanchang University· Source

• Not yet recruiting

  Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC

  NCT07596134· Zhejiang University· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

  NCT07833202· Phase 3· Shanghai Jeyou Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Treatment Strategy for Patients With RA-ILD

  NCT07643038· Phase 4· Chinese SLE Treatment And Research Group· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Not yet recruiting

  Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

  NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

  NCT07700667· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

  NCT07655622· Phase 1/2· Second Affiliated Hospital of Nanchang University· Source

• Enrolling by invitation

  Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec

  NCT07658417· Novo Nordisk A/S· Source

• Not yet recruiting

  Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD

  NCT07665359· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

  NCT07517042· Shanghai Zhongshan Hospital· Source

• Not yet recruiting

  Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

  NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Not yet recruiting

  Deep Sedation vs. General Anesthesia for Pulsed Field Ablation in Atrial Fibrillation

  NCT07621432· Second Affiliated Hospital of Nanchang University· Source

• Recruiting

  A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke

  NCT06459427· Yanbing Yu· Source

• Recruiting

  Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension

  NCT07607275· Phase 4· Beijing Anzhen Hospital· Source

• Recruiting

  Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)

  NCT07587099· Gan Lijun· Source

• Recruiting

  Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

  NCT07571161· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

  NCT07041788· Phase 2· Second Affiliated Hospital of Nanchang University· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

  NCT07493265· Phase 2· Eisai Inc.· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

  NCT07402239· United Innomed(Shanghai) Limited· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)

  NCT07352891· Beijing Anzhen Hospital· Source

• Recruiting

  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

  NCT07398599· Second Affiliated Hospital of Nanchang University· Source

• Not yet recruiting

  To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

  NCT07406438· Phase 1· Shenzhen Kexing Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· BeOne Medicines· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Not yet recruiting

  Left Ventricular Myocardial Work for Predicting Response to CRT

  NCT07319065· First Hospital of China Medical University· Source

• Recruiting

  Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

  NCT07307235· Phase 4· Shanghai Zhongshan Hospital· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

  NCT07176650· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  BDB-001 Phase III Trial in ANCA-Associated Vasculitis

  NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source

• Recruiting

  IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

  NCT07198841· Phase 2· Guangdong Association of Clinical Trials· Source

• Recruiting

  A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

  NCT07641634· Phase 1/2· Prolium Bioscience, Inc· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Daiichi Sankyo· Source

• Recruiting

  PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer

  NCT07775820· Nanfang Hospital, Southern Medical University· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration

  NCT07296575· Second Affiliated Hospital of Nanchang University· Source

• Recruiting

  An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

  NCT07200375· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· BioNTech SE· Source

Showing 50 of 132.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer20 recruiting
• Liver and biliary tract cancer8 recruiting
• Stroke7 recruiting
• High blood pressure6 recruiting
• Heart failure5 recruiting
• Gastric and oesophageal cancer4 recruiting
• Hepatitis B4 recruiting
• Alzheimer disease3 recruiting
• Atrial fibrillation3 recruiting
• Type 2 diabetes3 recruiting
• Acute myeloid leukaemia2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Lupus (SLE)2 recruiting
• Multiple myeloma2 recruiting
• Obesity2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Head and neck cancer1 recruiting
• IgA nephropathy1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Myasthenia gravis1 recruiting
• Narcolepsy1 recruiting
• Neuroendocrine tumours1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

  NCT07060885· Phase 3· ALK-Abelló A/S· Source

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

  NCT06975514· Phase 3· Shanghai Haiyan Pharmaceutical Technology Co., Ltd.· Source

• Completed

  Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

  NCT06880081· Phase 1· Chongqing Peg-Bio Biopharm Co., Ltd.· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Terminated

  A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

  NCT06487559· Phase 1· AbbVie· Source

• Completed

  Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

  NCT06553456· Phase 2/3· Beijing Protgen Biotechnology Development Co., Ltd.· Source

• Completed

  Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06415773· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Recruiting

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06477237· Phase 3· Huabo Biopharm Co., Ltd.· Source

• Recruiting

  A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

  NCT06179069· Phase 1· Zai Lab (Shanghai) Co., Ltd.· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Optimizing Early Nutrition Support in Severe Stroke-2

  NCT05998902· Phase 3· Wen Jiang-3· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06092762· Phase 2· Akeso· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study of Daridorexant in Chinese Patients With Insomnia Disorder

  NCT06010693· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

• Completed

  Evaluating Different Doses of Orelabrutinib in MCL

  NCT05978739· Phase 2· InnoCare Pharma Inc.· Source

• Completed

  A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

  NCT06103825· Phase 3· Ignis Therapeutics (Suzhou) Limited· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke

  NCT05719688· Suzhou Hengruihongyuan Medical Technology Co. LTD· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale

  NCT05546320· Phase 2· Chinese Academy of Medical Sciences, Fuwai Hospital· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

  NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

  NCT05092841· Phase 3· Tasly GeneNet Pharmaceuticals Co., Ltd· Source

• Completed

  A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

  NCT05004350· Phase 2· Pierre Fabre Medicament· Source

• Completed

  A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

  NCT04948697· Phase 2· BeiGene· Source

• Terminated

  Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04921358· Phase 3· BeiGene· Source

• Completed

  Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

  NCT04768075· Phase 3· Guangdong Association of Clinical Trials· Source

• Completed

  Research on AIS Recurrence Risk Prediction Model Using XGBoost Combined With Convolutional Neural Network Algorithm

  NCT06796283· Second Affiliated Hospital of Nanchang University· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Eli Lilly and Company· Source

• Completed

  Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

  NCT04643470· Phase 2· BeiGene· Source

• Completed

  Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

  NCT04723004· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

  NCT04205812· Phase 3· Incyte Corporation· Source

• Completed

  A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

  NCT04830826· The First Affiliated Hospital of Guangzhou Medical University· Source

• Completed

  TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03952091· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

  NCT03783442· Phase 3· BeiGene· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· BeiGene· Source

• Recruiting

  Neurovascular Product Surveillance Registry

  NCT02988128· Medtronic Neurovascular Clinical Affairs· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer70 works · 13 trials
• IgA nephropathy11 works · 2 trials
• Pulmonary arterial hypertension10 works · 0 trials
• Graves' disease and hyperthyroidism6 works · 0 trials
• Vascular dementia4 works · 0 trials